News, Events & Resources | Crystal Bio Solutions

Integrated Summary of Immunogenicity (ISI): What It Contains and Why It Matters

Written by CBS Marketing Team | Nov 22, 2026, 5:58:44 PM

Regulators expect sponsors of biologics to show how anti-drug antibodies (ADA) affect pharmacokinetics (PK), pharmacodynamics (PD), safety, and efficacy. The Integrated Summary of Immunogenicity (ISI) is where that story comes together in a marketing application. This article explains what the ISI covers, where it sits in the Common Technical Document (CTD), and why it pays to start it early.

Why immunogenicity is a regulatory focus

Biologics such as monoclonal antibodies, vaccines, and recombinant proteins are a major part of today's pipelines, and regulatory expectations for them keep rising. The FDA and other health authorities expect companies to evaluate the immune response to a biologic, because an unwanted immune response can reduce efficacy and create safety risks. Nonclinical and clinical immunogenicity assessment has therefore become a standard part of development.

A short primer on immunogenicity

In drug development, immunogenicity is the ability of a product to trigger an adaptive immune response in humans or animals. After a biologic enters the body, antigen-presenting cells (APCs) take it up, process it, and present peptides to CD4+ T cells. T cells that recognize the antigen become activated and work with B cells to produce antibodies that can neutralize and clear the drug.

The response depends on both the product and the patient. Product factors include structure, modifications, aggregates, and impurities. Patient factors include disease state, immune status, treatment history, and genetics. Because every patient's immune system is different, immunogenicity has to be characterized before approval.

Why ADA assessment is required

The main concern in practice is ADA formation. Some ADA are neutralizing antibodies (NAb), which block the drug's activity and reduce efficacy. If the biologic has an endogenous counterpart with an important physiological role, NAb can cross-react with the endogenous molecule and cause long-lasting adverse effects.

ADA responses can also cause immediate reactions, including life-threatening anaphylaxis, and milder ones such as injection-site reactions and dermatitis that still affect quality of life. Because of these risks to PK, PD, safety, and efficacy, a marketing application should include a comprehensive ADA assessment: the ISI. Immunogenicity assessment should continue throughout development.

What an ISI contains

The ISI gives reviewers an integrated view of the product's immunogenicity profile. It is usually organized in four parts:

  1. Risk factor analysis. How product class, physical and chemical properties, dosing regimen, disease characteristics, and patient characteristics affect immunogenicity risk.
  2. Risk-based immunogenicity plan. The bioanalytical strategy and other experimental methods, with a summary of the clinical study designs.
  3. Immunogenicity results. The relationship between ADA and PK, PD, safety, and efficacy, plus ADA characterization: incidence, prevalence, titer, NAb prevalence, and sometimes domain specificity.
  4. Immunogenicity risk conclusions. Immunogenicity weighed against clinical benefit and risk, including the risk mitigation plan.

Where the ISI sits in the CTD

The ISI is mainly presented in CTD Module 5.3.5.3 (reports of analyses of data from more than one study) and Module 2.7.2.4 (special studies). Module 2.5.3 (overview of clinical pharmacology) may also include ISI content.

Regulators do not mandate a standard ISI format. They do expect a complete and adequate assessment of how ADA affect PK, PD, safety, and efficacy at the population, subpopulation, and individual level.

Why start the ISI early

FDA guidance supports using the ISI from Phase 1 through the BLA and after approval. Starting it early lets the sponsor identify risks sooner, put mitigation strategies in place, and keep the document current as data accumulate. In practice, many companies have limited in-house experience with immunogenicity assessment and with regulators' expectations for how it is characterized and reported, so the ISI often becomes a late scramble.

As new and modified biologics, including bispecifics and ADCs, keep entering the clinic, early immunogenicity risk assessment is no longer optional. It improves the technical and regulatory success of a program.

How Crystal Bio Solutions can help

Crystal Bio Solutions develops and validates ADA and NAb assays and supports the integration of immunogenicity data with PK and clinical outcomes. Learn more about our ADA and NAb immunogenicity testing, or contact our team to discuss your program.

References

  • FDA. What Are "Biologics" Questions and Answers. fda.gov
  • 21 CFR Part 600, Biological Products: General. ecfr.gov
  • EMA. Guideline on Immunogenicity Assessment of Therapeutic Proteins, Rev. 1. ema.europa.eu
  • EMA. ICH M4E(R2) Common Technical Document: Efficacy. ema.europa.eu